VC
RNAC icon

Vivo Capital’s Cartesian Therapeutics RNAC Stock Holding History

Vivo Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-31,573
Closed -$2.35M – 66
2020
Q3 		$2.35M Sell
31,573
-43,620
-58% -$3.34M 0.14% 61
2020
Q2 		$6.41M Sell
75,193
-186,357
-71% -$16.9M 0.46% 41
2020
Q1 		$18.9M Buy
+261,550
New +$25.3M 1.71% 14
2019
Q3 		– Sell
-18,202
Closed -$977K – 25
2019
Q2 		$977K Hold
18,202
– – 0.09% 43
2019
Q1 		$1.29M Hold
18,202
– – 0.13% 46
2018
Q4 		$1.45M Sell
18,202
-7,173
-28% -$1.64M 0.19% 39
2018
Q3 		$11.8M Sell
25,375
-645
-2% -$259K 1.19% 22
2018
Q2 		$10.3M Sell
26,020
-11,286
-30% -$4M 1.33% 20
2018
Q1 		$11.4M Hold
37,306
– – 1.62% 16
2017
Q4 		$11M Hold
37,306
– – 2.35% 14
2017
Q3 		$20.4M Hold
37,306
– – 4.13% 8
2017
Q2 		$22.2M Buy
+37,306
New +$16.5M 5.6% 6

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vivo Capital's RNAC Position: Q4 2020 in Review

Vivo Capital sold out of Cartesian Therapeutics (RNAC) in Q4 2020, closing a stake of 31,573 shares — an estimated $2.35M sold.

Vivo Capital first reported a position in RNAC in Q2 2017 and held it in 12 quarters. The position peaked at $22.2M in Q2 2017. 95 funds tracked by Wall St. Rank hold RNAC as of Q4 2020.

  • Vivo Capital reported no remaining Cartesian Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Vivo Capital sold 31,573 Cartesian Therapeutics shares in Q4 2020, an estimated $2.35M.
  • Vivo Capital first reported a position in Cartesian Therapeutics in Q2 2017 and held it in 12 quarters.
  • Vivo Capital's Cartesian Therapeutics position peaked at $22.2M in Q2 2017.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2020.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.